THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease. Learn more.

Sagimet Biosciences Inc. (Nasdaq: SGMT), clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial ...

In a recent Fox News interview, the newly enshrined Health and Human Services secretary touted the benefits of supplements ...

TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitorFirst-in-human Phase 1 trial initiation planned in 2025SAN MATEO, Calif., ...

Discover the 5 ways alcohol progressively harms your liver, from early warning signs to serious complications, plus expert ...

Fatty pancreas disease, characterized by intra-pancreatic fat deposition, is more prevalent than diabetes, pancreatitis, and ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...

Liver fibrosis is a major global health concern, developing as a result of chronic liver diseases (CLDs) such as viral ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...

Researchers at Georgetown University have developed a new drug called CTPI-2, which targets a key gene known as Slc25a1. This ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...

Doctors warn, fatty liver can lead to liver cancer if ignored! Here's how to prevent non-alcoholic fatty liver disease.